Mississippi Board of Pharmacy Peptide Q&A on COAs and Dosing Advice

A certificate of analysis will not protect a Mississippi pharmacy that compounds a research-grade peptide, and a “not for human use” label will not protect the clinician who recommends one. The Mississippi Board of Pharmacy spelled out both points in its October 2026 newsletter, which answers licensees’ questions about a peptide statement the state’s pharmacy, medical, and nursing boards issued together on August 19.

The question-and-answer section also treats dosing instructions as a recommendation, whether a provider gives them directly or points patients to a website it does not control. A separate notice in the same issue tells pharmacies to confirm that out-of-state doctors and nurse practitioners treating Mississippi patients by telehealth hold a Mississippi license. Together, the answers reach peptide clinics, the pharmacies that fill their prescriptions, and the online programs that connect patients with both.

What the August joint statement prohibits

The Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides was signed by Kenneth Cleveland, M.D., executive director of the Mississippi State Board of Medical Licensure; Phyllis Polk Johnson, executive director of the Mississippi Board of Nursing; and Susan McCoy, R.Ph., executive director of the Mississippi Board of Pharmacy. It says that “under no circumstances” may a healthcare provider compound, administer, or dispense a non-FDA-approved or research-grade peptide to a patient, and that the prohibition “includes advising, recommending, supplying, prescribing, and administering.”

The statement requires providers to buy all prescription products, drugs, and ingredients from an entity permitted by the Mississippi Board of Pharmacy. It invites reports about unlicensed entities that sell or ship those products into the state. Patient consent forms that label a product “research-grade” do not reduce a provider’s professional or legal liability, according to the boards. A patient who buys and injects a peptide alone carries that risk alone, but any role a medical professional plays in recommending, supplying, prescribing, or administering it “constitutes the practice of medicine and is prohibited.”

Why a certificate of analysis falls short

A certificate of analysis (COA) is the lab report that typically ships with a bulk ingredient and states its identity and purity. The board’s newsletter says a COA “alone does not satisfy the concerns of the statement.” To compound a peptide from an active pharmaceutical ingredient (API), the board says the bulk substance must come from an FDA-registered establishment and the finished preparation must meet every exemption for compounding.

The newsletter lists what that means for the bulk substance. It must have a United States Pharmacopeia (USP) or National Formulary (NF) monograph, be a component of an FDA-approved drug, appear on the applicable FDA bulks list, or be actively listed under FDA’s Interim Category 1 policy. It also cannot be essentially a copy of a commercially available drug product.

The board also narrowed what “non-FDA-approved” means in the statement. “We recognize that no compounds are FDA-approved,” the newsletter says, adding that the intent “is not to forbid compounding that meets the criteria for allowed exemptions under federal and state laws.” The target is research-grade peptides and peptides with no valid compounding pathway under the 503A and 503B provisions of federal law, which govern traditional compounding pharmacies and outsourcing facilities.

Disclaimers and dosing pages

Two answers deal with how peptides are presented. Asked whether a statement that a peptide is not to be used in humans would ease concerns about advising or recommending it, the board answered no: “a disclaimer against human use would not remove the potential for enforcement action.”

The board then addressed dosing instructions, whether given directly or through an unaffiliated website. “Recommending a non-FDA-approved peptide, such as by directly or indirectly providing dosage or use instructions or information, is prohibited and could result in enforcement action,” the newsletter says.

The question describes an arrangement in which a provider keeps its own pages free of dosing claims but sends patients to a blog, calculator, or guide run by someone else. The board’s wording reaches indirect instructions, so a Mississippi provider that hands out such a link is in the same position as one that writes the dose on its own page. The newsletter does not say whether the board has opened cases on these grounds, and it does not describe penalties beyond enforcement action.

Telehealth prescribers need a Mississippi license

On the same page as the peptide answers, the board reminds pharmacies to verify that out-of-state doctors and nurse practitioners hold a Mississippi license when they provide telehealth services for Mississippi patients. It points to the Board of Medical Licensure’s verification search for doctors and to the Board of Nursing’s license verification page for nurse practitioners.

For a national telehealth program, that reminder means a Mississippi prescription can stall at the pharmacy if the prescriber’s license is from another state. Programs that route patients by state should check that every clinician assigned to Mississippi appears in the state lookup before the order reaches a pharmacy, because the board has told the pharmacies filling those orders to run the same check. Pharmacies and wholesalers selling into Mississippi can be verified through the Board of Pharmacy’s license verification site, which the newsletter calls the primary source of credential verification for its licensees, permittees, and registrants.

What sellers and their partners should check

The newsletter’s answers translate into a short list of questions for anyone selling peptide therapy to Mississippi patients:

Does every peptide on the menu have a compounding pathway the board recognizes, such as a USP monograph, an approved-drug component, or a place on an FDA bulks list?
Did the dispensing pharmacy buy its bulk ingredient from an FDA-registered establishment, with documentation beyond a COA?
Do product pages, emails, or linked third-party sites give dosing or use instructions for any research-grade peptide?
Does every prescriber treating Mississippi patients hold a Mississippi license that shows up in the state lookup?

The same file follows a clinic to its payment provider. A peptide clinic applying for card processing through Organic Payment Gateways or another high-risk provider will be describing its menu, its pharmacy, and its prescribers, the same three things the Mississippi board just put under scrutiny.

The board’s position in brief

Mississippi’s October newsletter turns the August peptide statement into concrete answers. A COA does not establish that a peptide can be compounded, a human-use disclaimer does not prevent enforcement, and dosing guidance counts as a recommendation even when it sits on someone else’s website. Compounding with a lawful pathway remains allowed, and the board’s telehealth reminder adds a licensing check for out-of-state prescribers. For peptide clinics, their pharmacies, and the telehealth programs between them, the test in Mississippi is now where the ingredient came from, who is advising the patient, and whether that person is licensed in the state.

Mississippi Pharmacy Board Says a Certificate of Analysis Does Not Clear Research-Grade Peptides